DNA mismatch repair deficiency test – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png DNA mismatch repair deficiency test – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Niraparib and Dostarlimab for Patients with DNA Repair-Deficient or Platinum-Sensitive Solid Tumors https://clinicaltrials.eu/trial/study-on-niraparib-and-dostarlimab-for-patients-with-dna-repair-deficient-or-platinum-sensitive-solid-tumors/ Wed, 29 Apr 2026 15:05:36 +0000 https://clinicaltrials.eu/trial/study-on-niraparib-and-dostarlimab-for-patients-with-dna-repair-deficient-or-platinum-sensitive-solid-tumors/ This clinical trial is focused on studying the effects of a combination of two medications, Niraparib and Dostarlimab, on certain types of cancer known as DNA repair-deficient or platinum-sensitive solid tumors. These are cancers that have difficulty repairing their DNA or respond to platinum-based chemotherapy. The purpose of the study is to evaluate how well these medications work together in treating these specific cancers.

The study involves administering Niraparib, which is taken as a tablet by mouth, and Dostarlimab, which is given as an infusion into a vein. Participants will receive these treatments over a period of up to 24 months. Throughout the study, the response of the tumors to the treatment will be monitored to assess the effectiveness and safety of the drug combination.

Participants will be regularly checked to see how their cancer is responding to the treatment and to monitor any side effects. The study aims to provide valuable information on whether this combination of medications can help improve outcomes for patients with these specific types of cancer.

]]>